JP2025516596A5 - - Google Patents
Info
- Publication number
- JP2025516596A5 JP2025516596A5 JP2024566352A JP2024566352A JP2025516596A5 JP 2025516596 A5 JP2025516596 A5 JP 2025516596A5 JP 2024566352 A JP2024566352 A JP 2024566352A JP 2024566352 A JP2024566352 A JP 2024566352A JP 2025516596 A5 JP2025516596 A5 JP 2025516596A5
- Authority
- JP
- Japan
- Prior art keywords
- binding molecule
- abs
- molecule according
- domain
- pcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340891P | 2022-05-11 | 2022-05-11 | |
| US63/340,891 | 2022-05-11 | ||
| US202363481291P | 2023-01-24 | 2023-01-24 | |
| US63/481,291 | 2023-01-24 | ||
| US202363489812P | 2023-03-13 | 2023-03-13 | |
| US63/489,812 | 2023-03-13 | ||
| PCT/US2023/066841 WO2023220647A1 (en) | 2022-05-11 | 2023-05-10 | Multispecific binding molecule proproteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516596A JP2025516596A (ja) | 2025-05-30 |
| JP2025516596A5 true JP2025516596A5 (OSRAM) | 2026-05-18 |
Family
ID=86760424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566352A Pending JP2025516596A (ja) | 2022-05-11 | 2023-05-10 | 多重特異性結合分子プロタンパク質及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250340668A1 (OSRAM) |
| EP (1) | EP4522649A1 (OSRAM) |
| JP (1) | JP2025516596A (OSRAM) |
| KR (1) | KR20250024872A (OSRAM) |
| CN (1) | CN119546628A (OSRAM) |
| AU (1) | AU2023269792A1 (OSRAM) |
| CA (1) | CA3252786A1 (OSRAM) |
| IL (1) | IL316892A (OSRAM) |
| WO (1) | WO2023220647A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4735043A1 (en) * | 2023-06-30 | 2026-05-06 | The Regents of the University of California | Pro-polypeptides and methods of using and designing the same |
| US20250297006A1 (en) * | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| ES2102007T3 (es) | 1992-01-23 | 1997-07-16 | Merck Patent Gmbh | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| HUE026278T2 (en) | 2003-07-01 | 2016-05-30 | Ucb Biopharma Sprl | Modified Fab antibody fragments |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| EP2611834B1 (en) | 2010-09-01 | 2018-03-07 | Biogen MA Inc. | Rapid generation of anti-idiotypic antibodies |
| MX385344B (es) | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| ES2821753T3 (es) | 2013-03-15 | 2021-04-27 | Lilly Co Eli | Procedimientos de producción de Fab y de anticuerpos biespecíficos |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| AU2016333517B2 (en) | 2015-10-02 | 2023-09-07 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| ES3034233T3 (en) | 2016-01-22 | 2025-08-14 | MabQuest SA | Non-blocking pd1 specific antibodies |
| MA43724B1 (fr) | 2016-03-22 | 2023-06-28 | Hoffmann La Roche | Molécules bispécifiques de cellules t activées par une protéase |
| US11390676B2 (en) | 2016-10-13 | 2022-07-19 | Symphogen A/S | Anti-LAG-3 antibodies and compositions |
-
2023
- 2023-05-10 CN CN202380053256.6A patent/CN119546628A/zh active Pending
- 2023-05-10 KR KR1020247040922A patent/KR20250024872A/ko active Pending
- 2023-05-10 US US18/864,231 patent/US20250340668A1/en active Pending
- 2023-05-10 AU AU2023269792A patent/AU2023269792A1/en active Pending
- 2023-05-10 WO PCT/US2023/066841 patent/WO2023220647A1/en not_active Ceased
- 2023-05-10 EP EP23730326.8A patent/EP4522649A1/en active Pending
- 2023-05-10 IL IL316892A patent/IL316892A/en unknown
- 2023-05-10 JP JP2024566352A patent/JP2025516596A/ja active Pending
- 2023-05-10 CA CA3252786A patent/CA3252786A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519974A5 (OSRAM) | ||
| JP2018537516A5 (OSRAM) | ||
| JP2023123502A5 (OSRAM) | ||
| JP2014530009A5 (OSRAM) | ||
| JP2022537824A5 (OSRAM) | ||
| IL256785B2 (en) | Chimeric polypeptide assembly and methods of making and using the same | |
| JP2021501570A5 (OSRAM) | ||
| JP2018524358A5 (OSRAM) | ||
| JP2024533309A5 (OSRAM) | ||
| JP2016501829A5 (OSRAM) | ||
| JP2019502746A5 (OSRAM) | ||
| JP2021511013A5 (OSRAM) | ||
| IL263616B1 (en) | Antibody adjuvant conjugates | |
| FI3824905T3 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| JP2023552998A5 (OSRAM) | ||
| RU2020116541A (ru) | Слитые белки однодоменное антитело-цитозиндезаминаза | |
| JP2017537627A5 (OSRAM) | ||
| JP2020506971A5 (OSRAM) | ||
| JP2019500894A5 (OSRAM) | ||
| Satta et al. | Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors | |
| WO2021032116A1 (zh) | 一种免疫细胞因子及其制备与用途 | |
| AR125758A1 (es) | Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras | |
| JP2021534769A5 (OSRAM) | ||
| CN117222421A (zh) | T细胞调节多肽和其使用方法 | |
| García-Martínez et al. | Immunotherapies in ovarian cancer |